Discover an innovative ultra-thin battery for smart contact lenses, powered by tears and inspired by ‘Mission Impossible.’
Category: biotech/medical – Page 547
Neuralink Could Head to the UK for Next Round of Clinical Trials as Brain-Computer Interface Startups Boom
Neuralink is onboarding patients in the UK in preparation for potential clinical trials amid a Brain-Computer Interface (BCI) boom.
Better farming through nanotechnology
(Nanowerk News) Advanced technologies enable the controlled release of medicine to specific cells in the body. Scientists argue these same technologies must be applied to agriculture if growers are to meet increasing global food demands.
In a new Nature Nanotechnology journal review paper (“Towards realizing nano-enabled precision delivery in plants”), scientists from UC Riverside and Carnegie Mellon University highlight some of the best-known strategies for improving agriculture with nanotechnology.
New bowel tumor drug helped cure cancer in 100% of cases
GSK announced a major breakthrough concerning cancer therapy. A drug called Jemperli (dostarlimab) showed impressive results in a phase 2 trial at the Memorial Sloan Kettering Cancer Center (MSK). The study included 42 patients suffering from mismatch repair deficient (dMMR) locally advanced rectal cancer, a type of bowel cancer.
Used as a first-line treatment and an alternative to chemotherapy and surgery, Jemperli cured cancer in all patients, showing “an unprecedented 100% clinical complete response rate.” Tests that followed showed no evidence of remaining tumors. Moreover, the first 24 of the 42 patients were observed after an average time of 26.3 months, and they showed no signs of cancer resurfacing.
GSK will test the drug in additional studies involving certain types of colorectal cancers.
New study redefines how antidepressants aid in treating major depressive disorder
Researchers from the University of Colorado Anschutz Medical Campus have established a new framework for understanding how classic antidepressants work in treating major depressive disorder (MDD), reemphasizing their importance and aiming to reframe clinical conversation around their role in treatment.
100% of Cancer Patients Cured Long-Term in ‘Remarkable’ Human Trial
In what researchers have called an “unprecedented” response, a new drug that treats locally advanced rectal cancer has shown to have completely eradicated tumors in all 42 patients who took part in the Phase II trial.
The drug, Jemperli (dostarlimab-gxly), had earlier shown great potential for eliminating mismatch repair deficient (dMMR) cancers, which make up 5–10% of colorectal cancers. Following the Phase II trial, the first 24 patients assessed showed a “sustained complete clinical response” – no cancer evident – after an average of 26.3 months.
“These findings demonstrate the potential of dostarlimab-gxly as a novel approach to treating locally advanced dMMR rectal cancer that leads to durable complete tumor regression without the need for life-altering treatment,” said Dr Andrea Cercek, researcher and oncologist at the Memorial Sloan Kettering Cancer Center (MSK). “As a clinician, I’ve seen firsthand the debilitating impact of standard treatment of dMMR rectal cancer and am thrilled about the potential of dostarlimab-gxly in these patients.”